The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
Open accessAbstract
BACKGROUND: Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance. METHODS: Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log(10) copies/mL from baseline or was <400 copies/mL. RESULTS: A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II (23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen. CONCLUSION: Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to RAL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Self-citationSubgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Self-citationMarkowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Self-citationvan Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70290-0 · Cited by 301
Self-citationDeJesus, E., Berger, D., Markowitz, M., Cohen, C., Hawkins, T., Ruane, P., Elion, R., Farthing, C., Zhong, L., Cheng, A. K., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233308.82860.2f · Cited by 270
Self-citationMarinello, J., Marchand, C., Mott, B. T., Bain, A., Thomas, C. J., & Pommier, Y. G. (2008) · Biochemistry · doi:10.1021/bi800791q · Cited by 142
Zolopa, A. R., Berger, D. S., Lampiris, H. W., Zhong, L., Chuck, S. L., Enejosa, J., Kearney, B. P., & Cheng, A. (2010) · The Journal of Infectious Diseases · doi:10.1086/650698 · Cited by 111
Garrido, C., Villacian, J. S., Zahonero, N., Pattery, T., García, F., Gutiérrez, F., Caballero, E., Houtte, M. V., Soriano, V., & de Mendoza, C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06170-11 · Cited by 64
Self-citationIntegrase inhibitors in the treatment of HIV-1 infection
Powderly, W. G. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq350 · Cited by 55
Cited by
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Self-citation2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.-M., Chas, J., Durant, J., Moreno, S., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu051 · Cited by 333
Self-citationHIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
Cottrell, M. L., Hadzic, T., & Kashuba, A. D. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0093-2 · Cited by 298
Metadata
- Authors
- Eron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C., Yeo, J., for the VIKING Study Group, Walmsley, S. L., Cox, J., Reynes, J., Morlat, P., Vittecoq, D., Livrozet, J.-M., Fernández, P. V., Gatell, J. M., DeJesus, E., DeVente, J., Lalezari, J. P., McCurdy, L. H., Sloan, L. A., Young, B., LaMarca, A., & Hawkins, T.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-07
- Volume
- 207
- Issue
- 5
- Pages
- 740-748
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2122026430
- Cited by
- 311
- References
- 11
- FWCI
- 22.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. https://app.cochat.ai/papers/10.1093/infdis/jis750
- The paper
- Eron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C., Yeo, J., for the VIKING Study Group, Walmsley, S. L., Cox, J., Reynes, J., . . . Hawkins, T. (2013). Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jis750
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.